A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.
Non-myeloid malignancy diagnosed by cytology/histology [+8]
Hematocrit (Hct) ≥ 36 vol% at the screening assessment. [+15]